Since the late 1980s, the anti-cancer properties of sweet wormwood artemisinin have been investigated in vitro  . After more detailed studies by Kelter G. in 2007, and Efferth T. in 2001, artemisinins were found to be active against a multitude of unrelated cancer cell lines, from the most common common types such as bowel, breast, and lung cancer. to leukemia and pancreatic cancer. Studies have also identified potential general mechanisms such as normalization of the increased Wnt / β-catenin pathway in colorectal cancer. Other pathways for anti-cancer activities include inhibition of increased tumor-associated angiogenesis.
The anti-cancer effect of sweet wormwood extract, Artemisinin, has been documented in human studies and individual clinical cases. Sweet wormwood extract, Artemisinin, has been used in cancer therapy, and has been shown to be easily tolerated and tolerated without significant side effects and side effects. It is hypothesized that iron-activated Artemisinin causes damage due to the release of highly acylated carbon-based radicals and radical oxygen species (ROS). Radicals may play a role in cell changes observed in Artemisinin-treated cells such as increased apoptosis, growth retardation, inhibition of angiogenesis, and DNA damage.
Before any drug can be made available to the public, it must first undergo rigorous research. The last step towards the approval of a drug for human use is a clinical trial. Clinical trials are research studies that involve humans. They are the last step in a long process that begins with research in the laboratory. Most of the treatments we use today are the result of past clinical trials. Clinical trials are one of the last steps in the long process of bringing a new pharmaceutical product to market. Before such a product is approved by regulatory authorities, its efficacy and safety in the target patient population must be demonstrated. The clinical development program for new products includes many clinical trials as well as tens of thousands of subjects.
The collected clinical evidence shows that Artemisinin and its derivatives promise treatment for laryngeal cancer, uveal malinoma and pituitary macroadenoma. Sweet wormwood extract is also in Phase I-II trials for the treatment of breast cancer, non-small cell lung cancer as well as colorectal cancer. Similarly, a 2008 clinical trial conducted by Zhang in 120 patients with advanced non-small cell lung cancer showed that sweet wormwood extract in combination with the vinorelbine and cisplatin chemotherapy regimen increased the one-year survival rate by 13% with a very high significant progress in disease control and time of progression, ie, disease progression. No additional side effects were reported.
In a 2006 study conducted by Singh and Panwar, a sweet wormwood extract, Artemisinin, was used to treat a seventy-five-year-old male patient suffering from pituitary macroadenoma. This patient had problems with sight, hearing and movement as a consequence of his illness. The patient consumed the sweet wormwood extract orally for a period of 12 months. Although the tumor remained the same in terms of size, CT scan showed a decrease in tumor density, and clinically, associated symptoms and signs improved significantly as therapy progressed. The patient also pointed out that he profited in many of these treatments. This, in fact, extended his life and improved the quality of his life. Overall, artemisinin treatment is very useful and effective in improving the quality of life of patients.
In another 2014 study conducted by Sanjeev, a randomized, placebo-controlled experimental study in which neither subjects nor researchers were aware of the fact when a drug was given to a patient was related to oral Artemisinin therapy for colorectal cancer and was applied to 20 patients. The primary goal of this study was to determine and determine the effects of sweet wormwood extract, Artemisinin, taken orally, in inducing apoptosis (programmed cell death) in patients awaiting colorectal adenocarcinoma surgery. Apoptosis in less than 7% of cells was seen in 67% and 55% of patients in the artemisinin and placebo groups, respectively. Therefore, Artemisinin has anti-proliferative properties in colorectal cancer and is generally well tolerated.
In 2008, Zhang designed a study to compare the efficacy and toxicity of Artemisinin treatment combined with NP (vinorelbine and cisplatin chemotherapy regimen) as well as NP alone in the treatment of advanced non-small cell lung cancer (NSCLC). One hundred and twenty cases of advanced NSCLC were randomly divided into a chemotherapy group as well as a group with combined Artemisinin and chemotherapy. Patients in the control group were treated with chemotherapy with vinorelbine and cisplatin. Patients in the study group were treated with a chemotherapy regimen supplemented with intravenous injections of Artemisinin. The disease control rate in the study group (88.2%) was significantly higher than in the control group (72.7%) (P< 0.05), and the time of disease progression in the study group (24 weeks) was significantly longer than in the control group (20 weeks). Therefore, Artemisinin combined with chemotherapy may increase the rate of disease control and prolong the time of disease progression in patients with advanced NSCLC without significant side effects.
Singh and Verma in 2002 noted that Artemisinin was successfully used in the treatment of squamous cell carcinoma of the larynx where treated patients showed a significant reduction in tumor size (up to 70%) after two months of treatment. Overall, Artemisinin therapy of patients has been of great benefit in prolonging and improving the quality of life. Without treatment, patients with laryngeal cancer die within 12 months.
Furthermore, Berger in 2005. proved that Artemisinin, used in combination with standard chemotherapy, increased survival and significantly reduced metastases in patients with malignant skin cancer. These patients with metastatic uveal melanoma were treated, after standard chemotherapy alone was ineffective in trying to stop the cancer from growing. This patient is still alive 47 months after he was first diagnosed with stage IV uveal cancer, a diagnosis with an average survival of about 2-5 months, with no additional side effects.
In the end, we conclude that the extract of sweet wormwood, Artemisinin, is largely non-toxic and it has been applied with related compounds to over 2 million patients, both children and adults, worldwide without reports of significant side effects and side effects. Also, Artemisinin is very affordable in terms of price, unlike conventional cancer drugs. The final result of current clinical trials, using Artemisinin as a therapy or adjunct against a wide range of cancerous diseases, has not yet been published although the original findings showed very positive results. Other cases describing the use of Artemisinin for the treatment of cancer were noted in the Cancer Smart Bomb in the first and second parts of the study (White, 2002).
 In laboratory conditions. (Literal translation from Latin: inside the glass). It refers to experimental biological studies conducted using components of an organism that have been isolated from their usual biological context, in order to allow a more detailed or appropriate analysis than would be possible with the whole organism.
Written by Dr. Benz Napoli